NCT00308269View on ClinicalTrials.gov

Study of Vintafolide (MK-8109, EC145) for the Treatment of Recurrent or Refractory Solid Tumors (MK-8109-006, EC-FV-01)

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

August 31, 2007

Study Completion Date

July 31, 2008

Conditions
Cancer
Interventions
DRUG

Vintafolide IV Bolus

Vintafolide is a folic acid desacetylvinblastine hydrazide conjugate

DRUG

Vintafolide IV Infusion

Vintafolide is a folic acid desacetylvinblastine hydrazide conjugate

Trial Locations (2)

21201

Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore

48201

Barbara Ann Karmanos Cancer Institute, Detroit

Sponsors

Lead Sponsor

Endocyte
All Listed Sponsors
lead

Endocyte

INDUSTRY

NCT00308269 - Study of Vintafolide (MK-8109, EC145) for the Treatment of Recurrent or Refractory Solid Tumors (MK-8109-006, EC-FV-01) | Biotech Hunter | Biotech Hunter